Advanced in Acute Promyelocytic Leukemia

Dr. Asad Bashey

Hematology | Oncology
Blood And Marrow Transplant Group Of Georgia
5670 Peachtree Dunwoody Rd Ne, Suite 1000, 
Atlanta, GA 
Accepting New Patients
Offers Telehealth
36 Years of Experience
Advanced in Acute Promyelocytic Leukemia
Blood And Marrow Transplant Group Of Georgia
5670 Peachtree Dunwoody Rd Ne, Suite 1000, 
Atlanta, GA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Asad Bashey is a Hematologist and an Oncologist in Atlanta, Georgia. Dr. Bashey has been practicing medicine for over 36 years and is rated as an Advanced provider by MediFind in the treatment of Acute Promyelocytic Leukemia. His top areas of expertise are Leukemia, Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Bashey is currently accepting new patients.

His clinical research consists of co-authoring 114 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Acute Promyelocytic Leukemia.

Specialties
Hematology
Oncology
Licenses
Specialist in GA
Hospital Affiliations
Northside Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alliant Health
  • HMO
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

BLOOD AND MARROW TRANSPLANT GROUP OF GEORGIA
5670 Peachtree Dunwoody Rd Ne, Suite 1000, Atlanta, GA 30342

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

S1803, Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients With Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
S1803, Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients With Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
Enrollment Status: Active_not_recruiting
Publish Date: September 15, 2025
Intervention Type: Drug
Study Drugs: Lenalidomide, Daratumumab/rHuPH20
Study Phase: Phase 3
A Phase 1 Study of Ipilimumab in Combination With Decitabine in Relapsed or Refractory Myelodysplastic Syndrome/Acute Myeloid Leukemia
A Phase 1 Study of Ipilimumab in Combination With Decitabine in Relapsed or Refractory Myelodysplastic Syndrome/Acute Myeloid Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: September 09, 2025
Intervention Type: Drug, Biological
Study Drugs: Decitabine, Ipilimumab
Study Phase: Phase 1
A Phase II, Open Label, Randomized, Two-Arm Study to Investigate the Efficacy and Safety of Two Doses of the Antibody Drug Conjugate GSK2857916 in Participants With Multiple Myeloma Who Had 3 or More Prior Lines of Treatment, Are Refractory to a Proteasome Inhibitor and an Immunomodulatory Agent and Have Failed an Anti-CD38 Antibody (DREAMM 2)
A Phase II, Open Label, Randomized, Two-Arm Study to Investigate the Efficacy and Safety of Two Doses of the Antibody Drug Conjugate GSK2857916 in Participants With Multiple Myeloma Who Had 3 or More Prior Lines of Treatment, Are Refractory to a Proteasome Inhibitor and an Immunomodulatory Agent and Have Failed an Anti-CD38 Antibody (DREAMM 2)
Enrollment Status: Completed
Publish Date: September 03, 2025
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin Frozen Liquid, Belantamab Mafodotin Lyophilized Powder
Study Phase: Phase 2
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)
Enrollment Status: Completed
Publish Date: August 19, 2025
Intervention Type: Other
Study Phase: Not Applicable
Phase II Trial Evaluating the Safety and Efficacy of Combined CD20- and BTK-Targeted B Cell Depleting Therapy With Rituximab and Ibrutinib in the Primary Treatment of Chronic Graft-Versus-Host Disease
Phase II Trial Evaluating the Safety and Efficacy of Combined CD20- and BTK-Targeted B Cell Depleting Therapy With Rituximab and Ibrutinib in the Primary Treatment of Chronic Graft-Versus-Host Disease
Enrollment Status: Terminated
Publish Date: December 13, 2024
Intervention Type: Drug
Study Drugs: Rituximab, Ibrutinib
Study Phase: Phase 2
A Phase II Study Evaluating the Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies
A Phase II Study Evaluating the Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies
Enrollment Status: Completed
Publish Date: November 07, 2023
Intervention Type: Drug, Procedure
Study Drugs: BL-8040 CD34-Positive Hematopoietic Cells, Hematopoietic Stem Cell Transplant
Study Phase: Phase 2
Phase II Trial of Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in High Risk AML Patients Who Are Not Eligible for Allogeneic Stem Cell Transplantation
Phase II Trial of Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in High Risk AML Patients Who Are Not Eligible for Allogeneic Stem Cell Transplantation
Enrollment Status: Completed
Publish Date: September 28, 2023
Intervention Type: Drug
Study Drugs: Fludarabine, Melphalan, Pembrolizumab
Study Phase: Phase 2
Use of Convalescent Plasma Collected From Donors Recovered From COVID-19 Virus Disease for Transfusion, as an Empirical and Preemptive Treatment During Viral Pandemic Outbreak
Use of Convalescent Plasma Collected From Donors Recovered From COVID-19 Virus Disease for Transfusion, as an Empirical and Preemptive Treatment During Viral Pandemic Outbreak
Enrollment Status: Terminated
Publish Date: November 14, 2022
Intervention Type: Biological
Study Drug: Anti-COVID-19 Plasma
Study Phase: Phase 2
A Phase II Trial of Nonmyeloablative Haploidentical Peripheral Blood Stem Cell Transplantation Followed By Maintenance Therapy With the Novel Oral Proteasome Inhibitor, MLN9708, in Patients With High-risk Hematologic Malignancies
A Phase II Trial of Nonmyeloablative Haploidentical Peripheral Blood Stem Cell Transplantation Followed By Maintenance Therapy With the Novel Oral Proteasome Inhibitor, MLN9708, in Patients With High-risk Hematologic Malignancies
Enrollment Status: Completed
Publish Date: September 02, 2021
Intervention Type: Drug
Study Drug: MLN9708
Study Phase: Phase 2
A Phase I/IB Study of Ipilimumab or Nivolumab in Patients With Relapsed Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation
A Phase I/IB Study of Ipilimumab or Nivolumab in Patients With Relapsed Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation
Enrollment Status: Completed
Publish Date: June 24, 2021
Intervention Type: Biological, Other
Study Phase: Phase 1
A Randomized, Double-blind Phase 3 Study of Vadastuximab Talirine (SGN-CD33A) Versus Placebo in Combination With Azacitidine or Decitabine in the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
A Randomized, Double-blind Phase 3 Study of Vadastuximab Talirine (SGN-CD33A) Versus Placebo in Combination With Azacitidine or Decitabine in the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Enrollment Status: Terminated
Publish Date: December 12, 2018
Intervention Type: Drug
Study Phase: Phase 3
A Unique Schedule of Palonosetron, Ondansetron, and Dexamethasone for the Prevention of Delayed Nausea and Vomiting in Patients Receiving Moderately Emetogenic Myeloablative Chemotherapy
A Unique Schedule of Palonosetron, Ondansetron, and Dexamethasone for the Prevention of Delayed Nausea and Vomiting in Patients Receiving Moderately Emetogenic Myeloablative Chemotherapy
Enrollment Status: Completed
Publish Date: April 17, 2017
Intervention Type: Drug
Study Phase: Phase 2
View 11 Less Clinical Trials

114 Total Publications

Primary Results From Blood and Marrow Transplant Clinical Trials Network 1702: Clinical Transplant-Related Long-Term Outcomes of Alternative Donor Allogeneic Transplantation.
Primary Results From Blood and Marrow Transplant Clinical Trials Network 1702: Clinical Transplant-Related Long-Term Outcomes of Alternative Donor Allogeneic Transplantation.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 18, 2025
Similar Doctors
Elite in Acute Promyelocytic Leukemia
Dr. Martha L. Arellano
Hematology | Oncology
Elite in Acute Promyelocytic Leukemia
Dr. Martha L. Arellano
Hematology | Oncology

Emory Medical Care Foundation Inc

80 Jesse Hill Jr Dr Se, 
Atlanta, GA 
 (11.0 miles away)
404-616-1000
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Martha Arellano is a Hematologist and an Oncologist in Atlanta, Georgia. Dr. Arellano is rated as an Elite provider by MediFind in the treatment of Acute Promyelocytic Leukemia. Her top areas of expertise are Acute Myeloid Leukemia (AML), Acute Promyelocytic Leukemia, Acute Lymphoblastic Leukemia (ALL), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Arellano is currently accepting new patients.

Scott R. Solomon
Advanced in Acute Promyelocytic Leukemia
Dr. Scott R. Solomon
Hematology | Oncology
Advanced in Acute Promyelocytic Leukemia
Dr. Scott R. Solomon
Hematology | Oncology

Blood And Marrow Transplant Group Of Georgia

Atlanta, GA 
 (2.3 miles away)
404-255-1930
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Scott Solomon is a Hematologist and an Oncologist in Atlanta, Georgia. Dr. Solomon is rated as a Distinguished provider by MediFind in the treatment of Acute Promyelocytic Leukemia. His top areas of expertise are Acute Myeloblastic Leukemia with Maturation, Acute Myeloblastic Leukemia without Maturation, Acute Myeloid Leukemia (AML), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Solomon is currently accepting new patients.

Manila Gaddh
Advanced in Acute Promyelocytic Leukemia
Dr. Manila Gaddh
Hematology
Advanced in Acute Promyelocytic Leukemia
Dr. Manila Gaddh
Hematology

Emory Winship Cancer Institute

1365 Clifton Road Northeast, BldgC, 
Atlanta, GA 
 (8.2 miles away)
404-778-1900
Experience:
25+ years
Languages Spoken:
English, Hindi, Punjabi, Urdu
See accepted insurances
Offers Telehealth

Manila Gaddh is a Hematologist in Atlanta, Georgia. Dr. Gaddh has been practicing medicine for over 25 years and is rated as a Distinguished provider by MediFind in the treatment of Acute Promyelocytic Leukemia. Her top areas of expertise are Venous Thromboembolism (VTE), Shwartzman Phenomenon, Deep Vein Thrombosis, Thrombocytopenia, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bashey's expertise for a condition
ConditionClose
View All 9 Distinguished Conditions
View All 11 Advanced Conditions
View All 22 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile